Changes in the Prevalence of Oncogenic HPV Types
Changes in the Prevalence of Oncogenic HPV Types
In Japan, nationwide prophylactic HPV vaccination was implemented in 2010; a bivalent vaccine
 was given from 2010 to 2012, and a quadrivalent vaccine from 2012. However, the program
 essentially ceased in June 2013.

 1. Our first objective is to examine the prevalence of 6, 11, 16, 18, 31, 33, 45, 52, and
 58 targeted by the nonavalent HPV vaccine in young Japanese women, and identify changes
 in the prevalence of these HPV types from 2011- 2012 (as reported in JHERS-2016;
 Sasagawa T, J Med Virol, 2016) to the present time (2020-2021). Especially, the
 investigators will focus on the prevalence of HPV16 and 18 in women aged 21-26 years and
 compare these data to those of the previous study.

 2. The investigators will assess the prevalence of HPV16 and 18 in women aged 16-18 years
 and compare these data to those of the HPV vaccine era (2010-2013).

 3. The investigators will explore the prevalence of other high-risk HPV types (35, 39, 51,
 56, 59, and 68), 11 probable high-risk types (26, 30,34, 53, 66, 67, 69, 70, 73, 82, and
 85), and SILs in Japanese young women, since these types might be causative HPV types
 for cervical cancer in the future after world-wide HPV vaccination.

 Currently, it is unclear whether HPV vaccination has reduced the prevalence of HPV16 and 18
 in Japan. Our previous study (JHERS-2016; performed during 2011-2012; Sasagawa T, J Med
 Virol, 2016), the only population-based study on HPV prevalence at the commencement of
 prophylactic HPV vaccination in Japan, included prevalence data for HPV types 6, 11, 16, and
 18 and the associated cervical abnormalities. The investigators hypothesize that the
 prevalence of HPV16 and 18 and the associated diseases (SILs) decreased significantly in
 women aged 21-26 years in the present, vaccinated group compared to that in similar aged
 women in 2010-2012 who were unvaccinated. In contrast, the prevalence of HPV and associated
 diseases may not differ in women aged 27-39 years between the two eras; such subjects may
 thus serve as a negative control group. Also, HPV prevalence may be higher in present women
 aged 16-18 years than in women in that age range during the vaccine era, as the former group
 have not been vaccinated against HPV.

 The prevalence rates of the other unique high-risk types, namely HPV35, 39, 51, 56, 59, and
 68, and probable high-risk types, HPV26, 20, 34, 53, 66, 67, 67, 70, 73, 82, and 85, are
 unlikely to have been affected by HPV vaccination. However, it is important to monitor the
 prevalences of these types and the associated SILs, because the types numbered above may
 become more significant as currently common HPV types are eliminated in the near future.
Recently, HPV prevalence has decreased dramatically in the USA (Markowitz LE, Pediatrics,
 2019). Surprisingly, the nonavalent vaccine optimally decreased the prevalence of the most
 common, high-risk HPV types and also reduced the incidence of premalignant cervical lesions
 (Mariani L, Int J Gynaecol Obstet, 2017). The data thus suggest that both the bivalent and
 quadrivalent HPV vaccines eliminate HPV16- and 18-associated cervical cancers.

 Regrettably, in Japan, use of the bivalent and quadrivalent prophylactic HPV vaccines almost
 ceased, by government decree, in June 2013 (Hanley JBS, Lancet, 2015). However, about 70% of
 girls aged 13-18 years were immunized with these vaccines during 2010-2012. A small decrease
 in cervical intraepithelial neoplasia grade 3 (CIN3) has been observed in 20-year-old
 Japanese women who underwent HPV vaccination (Yagi A, Vaccine, 2019).The investigators
 recently found nationwide (unpublished) data suggesting that the incidence of condyloma has
 decreased in Japanese women aged in their early twenties, but has apparently increased in
 males. The decrease in women may be attributable to quadrivalent HPV vaccination, which
 protects against HPV6 and 11 infections. Further work is necessary, as statistical analysis
 is lacking, and the proportion of quadrivalent vaccinations among all vaccinations is unknown
 in Japan.

 The investigators earlier reported a high prevalence of HPV infection and associated cervical
 abnormalities in 6,628 women aged 16-50 years. The work was performed from October 2011 to
 March 2012 and was reported in JHERS-2016 (Sasagawa T, J Med Virol, 2016). The investigators
 recorded demographic information including age, marital status, any history of or current
 sexually transmitted disease (STD), any cervical abnormalities, and any other gynecological
 problems. HPV genotyping (31 types) and the Pap test were performed for all subjects. This is
 the only study that has investigated HPV prevalence and cervical SILs in the general
 population. The information collected included sexual details and any history of HPV
 vaccination. Routine gynecological examination, the Pap test (employing liquid-based cytology
 [LBC]), and HPV genotyping of LBC samples were performed. These data allow us to compare the
 status of women in the vaccine and (present) no-vaccine era.

 It is possible to essentially eliminate cervical cancer by implementation of nanovalent HPV
 vaccination and careful cancer screening (HPV testing). However, some specialists suggest
 that reductions in certain HPV types might induce increases in other HPV types that are not
 targeted by vaccination and not tested during cancer screening. Not only the existing 13
 high-risk HPV types but also other HPV types considered to probably or possibly associated
 with high risk are found in some cervical cancer tissues (Halec G, J Pathology 2014). The
 investigators also found such HPV types in high-grade SILs, as reported in JHERS-2016
 (Sasagawa T, J Med Virol, 2016) and a recent publication (Sakamoto J, Papillomavirus Res,
 2019). Therefore, in the present project, the investigators will document the prevalence of
 all oncogenic HPV types, including the 13 recognized high-risk types and the probable
 high-risk types (HPV26, 30, 34, 53, 66, 67, 69, 70, 73, 82, and 85).
Inclusion Criteria:

 -  Japanese women who seek cervical cancer screening or gynecological consultations

 -  Women with benign conditions

 -  16-39 year-old

 -  Women must be sexually experienced, as defined by sexual contact (oral-genital or
 genital-genital) with at least one male or female partner.

 Exclusion Criteria:

 -  Women with STDs

 -  Women with premalignant lesions of the cervicovaginal tract

 -  Women suffering from any cancer

 -  Women with any severe acute or chronic disease, and/or psychological problems